Fact Sheet
IQVIA Cell and Gene Therapy Center
Driving stem cell development from candidate identification through market authorization

The focus in Regenerative Medicine (RMx) is changing from bench medicine to clinical-commercial success. RMx faces many headwinds: complex preclinical/nonclinical models, constrained clinical manufacturing capacity, limited clinical sites with RMx experience, shifting regulatory landscape and an unclear pathway for pricing and market access.

Working in close collaboration with the California Institute for Regenerative Medicine (CIRM), and our alliance partners, WuXi AppTec and City of Hope for manufacturing and CMC support, and Charles River Laboratories for preclinical/non-clinical research, the Cell and Gene Therapy Center provides a comprehensive suite of services to tackle the most pressing challenges in the field.

Contact Us